Polypharmacy leads to increased prevalence of potentially inappropriate medication in the Indonesian geriatric population visiting primary care facilities

Rizky Abdullah¹
Widya N Insani¹
Dika P Destiani¹
Nurul Rohmaniasari¹
Nithya D Mohenathas¹
Melisa I Barliana²

¹Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia; ²Department of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia

Background: The geriatric population is particularly vulnerable to being prescribed potentially inappropriate medication (PIM); however, the prevalence of this occurrence remains poorly investigated in Indonesia. Thus in this research, we focused on investigating the prevalence and predictors of PIM among the Indonesian geriatric population in a primary health care setting.

Methods: A retrospective observational study was conducted in 25 primary health care facilities in Karawang District, Indonesia. The medical prescriptions of patients aged ≥60 years during January–December 2014 were documented, and the PIM was assessed based on Beers and McLeod criteria. The influence of age, sex, number of diseases, and polypharmacy toward PIM was assessed using a logistic regression model. A P-value of <0.05 defined statistical significance.

Results: A total of 3,819 subjects were included in the study. PIM was highly prevalent (52.2%) among the Indonesian elderly. Chlorpheniramine, mefenamic acid, ibuprofen, and nifedipine were the most commonly prescribed PIM. Polypharmacy (odds ratio: 1.2 [0.6, 2.1]) was the only factor associated with the use of PIM, while sex, age, and multiple diseases did not show significant association.

Conclusion: PIM is a concern in the Indonesian geriatric population. Health care professionals are encouraged to review the medications of their geriatric patients using updated safety guidelines to prevent risks associated with PIM.

Keywords: potentially inappropriate medication, polypharmacy, geriatrics, adverse drug reactions, hospitalization

Introduction

The use of potentially inappropriate medication (PIM) is a major safety concern with serious health consequences.¹,² PIM encompasses the use of medication for which the risks outweigh the benefits, particularly when there is evidence of available alternative therapies that are safer and equally or more effective.³ It also includes the misuse of medicines, including inappropriate dose and duration.⁴

The geriatric population is at risk for PIM prescription. The existence of multiple comorbid conditions and altered pharmacokinetics and pharmacodynamics render this age group particularly vulnerable to inappropriate prescribing.⁵,⁶ Previous studies showed that the use of PIM in a geriatric population was associated with adverse drug reactions (ADRs), hospital admission, and mortality.⁷,⁹
Several assessment tools have been developed to detect inappropriate prescribing for the geriatric population, either based on implicit or explicit judgments.\textsuperscript{11-15} Unlike the implicit tools (eg, physicians assessment), the latter is more reproducible and is easier to apply in large-scale studies with minimal financial burden.\textsuperscript{16} One of the most widely used explicit tools with international acceptance is Beers criteria. It consists of a list of 53 inappropriate drugs that should be avoided by geriatric patients.\textsuperscript{17} Another criteria developed by Canadian consensus, the McLeod et al\textsuperscript{18} criteria, describes prescribing guidelines with clinical relevance for medications in the geriatric population.

There are numerous reports on the evaluation of PIM prescription and its predictors among the geriatric population in various regions. A review of studies conducted in Europe and the United States revealed that the prevalence of PIM reached 40%.\textsuperscript{19} In Brazil, 46.2% of total patients encounters used PIM.\textsuperscript{20} Within Asian countries, the prevalence of PIM was 21.1% and 32.7%, in Japan and Malaysia, respectively.\textsuperscript{21,22}

Indonesia is a country with a geriatric population that is growing at a rapid rate.\textsuperscript{23} However, there is very limited information regarding PIM use among the Indonesian geriatric population, particularly in primary health care facilities. Primary health care is the setting in which most Indonesian geriatric patients receive their medical care, particularly medication for chronic illnesses. Improving the quality of prescribing in primary health care is important to reduce preventable harm and unnecessary hospitalizations.\textsuperscript{24} Therefore, this study aimed to assess the prevalence and the predictors of PIM prescription among the Indonesian geriatric population visiting primary health care facilities in Karawang District, using Beers and McLeod criteria.

**Methods**

**Study design**

This was a retrospective observational study conducted at 25 primary health care facilities in Karawang District, Indonesia. The data source included both acute and chronic medical prescription records of the patients aged $\geq 60$ years during January–December 2014. There are varying definitions of the elderly, which may be due to differences of life expectancy in different geographic regions. We used the cut-off 60 years based on the recommendation of World Health Organization regional office for South-East Asia.\textsuperscript{25}

Assuming a prevalence rate of 20.4%,\textsuperscript{26} a minimum sample size of 662 was required (95% confidence level). The simple random sampling method was employed to select the study subjects. For each, the following data were obtained and documented: demographic characteristics, all prescribed medications with doses, and diagnoses.

The data accessed in this study were deidentified to protect the patients identity. This study was approved by the Health Research Ethics Committee of Universitas Padjadjaran, Indonesia, No 777/UN6.C1.3.2/KEPK/PN/2015. Informed consent of participants was not required as the retrospective study design did not affect the health care of included patients.

**PIM criteria**

Prescribing of PIM was evaluated using the updated Beers and McLeod criteria.\textsuperscript{17,18} The 2012 updated Beers criteria identified categories of drugs that should be avoided by geriatric populations, drugs that should be avoided in certain medical conditions, and drugs that should be used with caution. In this study, the assessment was based on the first set of criteria, as it has broad and straightforward application, which consists of 38 medications.\textsuperscript{17} In the McLeod guideline, we adopted the criteria related to drugs and doses that should be avoided by the geriatric population.\textsuperscript{18} Prevalence of PIM was calculated based on the number of patients with at least one PIM criteria in their medical prescription. The complete list of Beers and McLeod drugs criteria that used in this study can be seen in Table 1.

**Data analysis**

The percentage of prescriptions consisting of at least one PIM, either from Beers or McLeod criteria, was calculated. The pattern of the PIM was also recorded. We examined the association between age, sex, number of diseases, and number of medications toward PIM using a logistic regression model. Polypharmacy was defined by the use of $\geq 5$ medications.\textsuperscript{27,28} The results are expressed as odds ratios (ORs) with 95% CI. Statistical significance was set at $<0.05$.

Analysis was performed using Stata 11.2 (Stata Corp, College Station, TX, USA).

**Results**

During the study period, 6,519 records were selected. We excluded 2,700 records due to incomplete data for analysis. As presented in Table 2, a total of 3,819 subjects was included in this study. The mean age was 65.8 years old (SD 6.2), and the dominant group was female. The average number of diseases was 1.2 (SD 0.4). The number of drugs per record was in the range of 1–6, with an average of 3.3 (SD 0.8).
### Table 1 Criteria used to identify PiM based on Beers and McLeod et al criteria

| Drugs               | Beers | McLeod | Beers and McLeod |
|---------------------|-------|--------|------------------|
| **Anticholinergics**|       |        |                  |
| Brompheniramine     | ✓     |        |                  |
| Carboxinamme        | ✓     |        |                  |
| Chlorpheniramine    | ✓     |        |                  |
| Clemastine          | ✓     |        |                  |
| Cyproheptadine      | ✓     |        |                  |
| Dexampheniramine     | ✓     |        |                  |
| Dextrchlorpheniramine| ✓    |        |                  |
| Diphenhydramine     | ✓     |        |                  |
| Doxylamine          | ✓     |        |                  |
| Hydroxyzine         | ✓     |        |                  |
| Promethazine        | ✓     |        |                  |
| Triprolidine        | ✓     |        |                  |
| **Antidiarrheal**    |       |        |                  |
| Diphenoxylate       | ✓     |        |                  |
| **Antiparkinson**    |       |        |                  |
| Benztropine (oral)  | ✓     |        |                  |
| Trilhexyphenidyl    | ✓     |        |                  |
| **Vasodilator**      |       |        |                  |
| Nylidrin            | ✓     |        |                  |
| Pentoxifylline      | ✓     |        |                  |
| **Antispasmodic**    |       |        |                  |
| Belladonna alkaloids| ✓     |        |                  |
| Clidinium–chloridiazepoxide | ✓ |        |                  |
| Dicyclomine         | ✓     |        |                  |
| Hyoscymine          | ✓     |        |                  |
| Propantheline       | ✓     |        |                  |
| Scopolamine 20      | ✓     |        |                  |
| **Stimulant**        |       |        |                  |
| Methylpenidate      | ✓     |        |                  |
| **Antithrombotics**  |       |        |                  |
| Dipyridamole, oral short acting | ✓ | ✓ | ✓ |
| Ticlopidin          | ✓     |        |                  |
| **Analgesic & anti-inflammatory** |       |        |                  |
| Meperidine          | ✓     | ✓      | ✓                |
| Aspirin >325 mg/d   | ✓     | ✓      | ✓                |
| Diclofenac          | ✓     |        |                  |
| Diflunisal          | ✓     |        |                  |
| Etorolic           | ✓     |        |                  |
| Fenoprofen          | ✓     |        |                  |
| Ibufrofen           | ✓     |        |                  |
| Ketoprofen          | ✓     |        |                  |
| Meclofenamate       | ✓     |        |                  |
| Mefanamic acid      | ✓     | ✓      | ✓                |
| Meloxicam           | ✓     | ✓      | ✓                |
| Nabumetone          | ✓     |        |                  |
| Naproxen            | ✓     | ✓      | ✓                |
| Oxaprozin           | ✓     | ✓      | ✓                |
| Piroxicam           | ✓     | ✓      | ✓                |
| Sulindac            | ✓     |        |                  |
| Tolmetin            | ✓     |        |                  |
| Indomethacin        | ✓     | ✓      | ✓                |
| Ketorolac, includes parenteral | ✓ | ✓ | ✓ |
| Pentazocine         | ✓     | ✓      | ✓                |

(Continued)
Table 1 (Continued)

| Drugs                              | Beers | McLeod | Beers and McLeod |
|------------------------------------|-------|--------|------------------|
| Oxazepam                           | ✓     |        | ✓                |
| Temazepam                           | ✓     |        |✓                 |
| Triazolam                          | ✓     | ✓      |✓                 |
| Clorazepate                        | ✓     |        |✓                 |
| Chlordiazepoxide                   | ✓     | ✓      |✓                 |
| Chlordiazepoxide–amitriptyline     | ✓     |        |✓                 |
| Clidinium–chlordiazepoxide         | ✓     |        |✓                 |
| Clonazepam                         | ✓     |        |✓                 |
| Diazepam                           | ✓     | ✓      |✓                 |
| Flurazepam                         | ✓     | ✓      |✓                 |
| Quazepam                           | ✓     |        |✓                 |
| Chloral hydrate                    | ✓     |        |✓                 |
| Meprobamate                        | ✓     |        |✓                 |
| Eszopiclone                        | ✓     |        |✓                 |
| Zolpidem                           | ✓     |        |✓                 |
| Zaleplon                           | ✓     |        |✓                 |
| Ergot mesylates                    | ✓     |        |✓                 |
| Isoxsuprine                        | ✓     |        |✓                 |
| Skeletal muscle relaxants          |       |        |✓                 |
| Carisoprodol                       | ✓     | ✓      |✓                 |
| Chlorzoxazine                      | ✓     | ✓      |✓                 |
| Cyclobenzaprine                    | ✓     | ✓      |✓                 |
| Metaxalone                         | ✓     | ✓      |✓                 |
| Methocarbamol                      | ✓     | ✓      |✓                 |
| Orphenadrine                       | ✓     | ✓      |✓                 |
| Endocrine                          |       |        |✓                 |
| Methyltestosterone                 | ✓     |        |✓                 |
| Testosterone                       | ✓     |        |✓                 |
| Desiccated thyroid                 | ✓     |        |✓                 |
| Estrogens with or without progestins | ✓     |        |✓                 |
| Growth hormone                     | ✓     |        |✓                 |
| Insulin, sliding scale             | ✓     |        |✓                 |
| Megestrol                          | ✓     |        |✓                 |
| Chlorpropamide                     | ✓     |        |✓                 |
| Glyburide                          | ✓     |        |✓                 |
| Gastrointestinal                   |       |        |✓                 |
| Metoclopramide                     | ✓     |        |✓                 |
| Mineral oil, oral                  | ✓     |        |✓                 |
| Trimethobenzamide                  | ✓     |        |✓                 |

Note: American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–631, with permission from John Wiley and Sons. Reproduced with permission from McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ. 1997;156(3):385–391. Abbreviation: PIM, potentially inappropriate medication.

Results of the prevalence of PIM in this study can be seen in Table 3. We found that the overall prevalence of PIM was 52.2% (n=1,994) among the included records. Most of the PIM-prescribed medications are designated in the Beers criteria (75%). There are lists of drugs that were included in both the Beers and McLeod criteria, from which 24% of the PIM were prescribed. The most frequently prescribed PIMs were chlorpheniramine, mefenamic acid, ibuprofen, and nifedipine.

Meanwhile, as presented in Table 4, PIM prescription was not associated with age, sex, multiple diseases, and the use of ≤4 medications. Polypharmacy was an independent predictor of PIM, with an adjusted OR of 1.6 (1.2, 2.1), \( P \)-value =0.001. Furthermore, as can be seen in Table 5, the prevalence of PIM of patients receiving polypharmacy (5 or more drugs) was 63.5%, which was higher than those of nonpolypharmacy.

**Discussion**

In this study, we examined the prevalence of PIM among the Indonesian geriatric population in a primary care setting in the Karawang district. Its predictors were also determined to identify vulnerable groups prone to PIM and to better target intervention for reducing PIM. Assessment of PIM in primary care setting provides an overview of medication use pattern in the first point of contact with health professional. Appropriate initial treatment can prevent more serious complications among the elderly. The use of PIM was highly prevalent among the study subjects (52.2%), implying the urgent need for improvement.
Due to variabilities in the research setting, duration, and other criteria, a comparison with other studies was not straightforward. Despite these variations, we found that our results were comparable with previous findings. Slightly higher PIM was observed in studies conducted among the Japanese elderly in acute care, with a PIM prevalence of 56.1%, and among elderly surgical patients in US hospitals (55.3%). On the other hand, a lower prevalence rate (32.2%) was observed in a study conducted in a UK primary care setting. Among other developing countries, the results of the current study were relatively much lower, for example, compared to those in Brazilian nursing homes (82.6%) and in an Indian teaching hospital (87.3%). The variations of these rates could be due to the differences in access to medicines, prescribing practices, and routine assessment of prescriptions by pharmacists.

In our study, the most frequently used PIM was chlorpheniramine, a first-generation antihistamine. It is strongly advised that this medication not be prescribed due to its high anticholinergic activity and increased risk of toxicity due to reduced clearance. Accidental deaths of the elderly under the influence of chlorpheniramine were reported in Japan. Use of a second-generation antihistamine is recommended due to lower lipophilic properties, contributing to the prevention of the development of ADRs in the central nervous system.

Table 4 Results of logistic regression analysis

| Characteristics      | OR (CI)   | P-value |
|----------------------|----------|---------|
| Age (years)          |          |         |
| 60–69                | 0.9 (0.8, 1.1) | 0.661   |
| 70–79                | 1.0 (0.9, 1.2) | 0.578   |
| ≥80                  | 0.9 (0.6, 1.3) | 0.829   |
| Sex                  |          |         |
| Male                 | 0.9 (0.8, 1.0) | 0.159   |
| Female               | Ref      |         |
| Number of diseases   |          |         |
| 1                    | 0.9 (0.8, 1.1) | 0.668   |
| 2                    | 1.0 (0.8, 1.2) | 0.778   |
| ≥3                   | 1.1 (0.6, 2.0) | 0.620   |
| Number of medication |          |         |
| 0–4 medications      | 0.9 (0.7, 1.3) | 0.927   |
| ≥5 medications       | 1.6 (1.2, 2.1) | 0.001   |

Abbreviations: OR, odds ratio; Ref, reference.

Table 5 Relationship between number of drugs and prevalence of PIM

| Number of medication | n   | PIM (%) |
|----------------------|-----|---------|
| 1–2                  | 507 | 223 (44) |
| 3–4                  | 3,104 | 1,651 (53.2) |
| ≥5                   | 208  | 132 (63.5) |
| Total                | 3,819 | 2,006 (52.5) |

Abbreviation: PIM, potentially inappropriate medication.
advantages, including its straightforward application for large sample size and acceptable reliability, as opposed to implicit measures which rely on subjective clinical judgment of researchers.52

The number of PIMs observed with the Beers criteria was higher than that observed with the McLeod criteria. Most drugs included in the McLeod criteria were included in the 2012 updated Beers criteria, indicating that the Beers set of criteria is an important prescribing assessment tool.17,18 However, the list may not always be suitable for implementation in all countries due to the different varieties of drugs registered and other prescribing practices. Therefore, there is a need to develop PIM criteria for specific countries.

This study, however, still has limitations. As only 25 primary health care facilities in Karawang District were involved, the generalizability of this result for the entire Indonesian geriatric population is limited. Furthermore, the association between the prevalence of PIM to ADR in patients receiving PIM was not assessed due to difficulties in collecting comprehensive patient medical data.

Conclusion
The prevalence of PIM in the current study was considerably high (55.2%), with polypharmacy found to be an independent predictor. Health care professionals are encouraged to review the medications prescribed for geriatric patients using updated safety guidelines to prevent the risks associated with PIM.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Cahir C, Bennett K, Teljeur C, Fahey T. Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients. Br J Clin Pharmacol. 2014;77(1):201–210.
2. Wallace E, McDowell R, Bennett K, Fahey T, Smith SM. Impact of potentially inappropriate prescribing on adverse drug events, health related quality of life and emergency hospital attendance in older people attending general practice: a prospective cohort study. J Gerontol A Biol Sci Med Sci. 2017;72(2):271–277.
3. Laroche ML, Charmes JP, Bouthier F, Merle L. Inappropriate medications in the elderly. Clin Pharmacol Ther. 2009;85(1):94–97.
4. Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370(9582):173–184.
5. Lavan AH, Gallagher PF, O’Mahony D. Methods to reduce prescribing errors in elderly patients with multimorbidity. Clin Interv Aging. 2016;11:857–866.
6. Ananthanam S, Powis RA, Cracknell AL, Robson J. Impact of prescribed medications on patient safety in older people. Ther Adv Drug Saf. 2012;3(4):165–174.
7. Hedna K, Hakkarainen KM, Gyllensten H, Jonsson AK, Petzold M, Hagg S. Potentially inappropriate prescribing and adverse drug reactions in the elderly: a population-based study. Eur J Clin Pharmacol. 2015;71(12):1525–1533.
8. do Nascimento MM, Mambrini JV, Lima-Costa MF, Firmino JO, Peixoto SW, de Loyola Filho AJ. Potentially inappropriate medications: predictor for mortality in a cohort of community-dwelling older adults. Eur J Clin Pharmacol. 2017;73(5):615–621.
9. Albert SM, Colombo A, Hanlon J. Potentially inappropriate medications and risk of hospitalization in retirees: analysis of a US retiree health claims database. Drugs Aging. 2010;27(5):407–415.
10. Jeon HL, Park J, Han E, Kim DS. Potentially inappropriate medication and hospitalization/emergency department visits among the elderly in Korea. Int J Qual Health Care. 2018;30(1):50–56.
11. Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011;12(7):601–610.
12. Oliveira MG, Amorim WW, de Jesus SR, Rodrigues VA, Passos LC. Factors associated with potentially inappropriate medication use by the elderly in the Brazilian primary care setting. Int J Clin Pharm. 2012;34(4):626–632.
13. Ramhade S, Chakarborthy A, Shrivastava A, Patil UK, Ramhade A. A survey on polypharmacy and use of inappropriate medications. Toxicol Int. 2012;19(1):68–73.
14. Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey. JAMA. 2001;286(22):2823–2829.
15. Ryan C, O’Mahony D, Kennedy J, Weedle P, Byrne S. Potentially inappropriate prescribing in an Irish elderly population in primary care. Br J Clin Pharmacol. 2009;68(6):936–947.
16. Kim DS, Heo SI, Lee SH. Development of a list of potentially inappropriate drugs for the Korean elderly using the Delphi method. Healthc Inform Res. 2010;16(4):231–252.
17. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–631.
18. McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ. 1997;156(3):385–391.
19. Gallagher P, Barry P, O’Mahony D. Inappropriate prescribing in the elderly. J Clin Pharm Ther. 2007;32(2):113–121.
20. Castellar JI, Karnikowski MGO, Vianna LG, Nóbrega OT. A study of pharmacotherapy prescribed to the elderly in a long-stay institution in Brazil. Acta Med Port. 2007;20:97–105.
21. Chen LL, Tangiisuran B, Shafie AA, Hassali MA. Evaluation of potentially inappropriate medications among older residents of Malaysian nursing homes. Int J Clin Pharm. 2012;34(4):596–603.
22. Niwata S, Yamada Y, Ikegami N. Prevalence of inappropriate medication use in older adults. J Clin Pharm Ther. 2006;32(2):113–121.
23. Samra R, Bottle A, Aylin P. Monitoring patient safety in primary care: an exploratory study using in-depth semistructured interviews. BMJ Open. 2015;5(9):e008128.
24. Cao J, Rammoohan A. Social capital and healthy ageing in Indonesia. BMC Public Health. 2016;16:631.
25. World Health Organization. Health situation and trend assessment. Elderly population. Geneva: World Health Organization; 2018. Available from: http://www.searo.who.int/entity/health_situation_trends/data/chi/elderly-population/en/. Accessed May 12, 2018.
26. Ernawati DK, Lee YP, Hughes JD. Nature and frequency of medication errors in a geriatric ward: an Indonesian experience. Ther Clin Risk Manag. 2014;10:413–421.
27. Hanlon JT, Schmader KE, Ruby CM, Weinberger M. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc. 2001;49(2):200–209.
28. Klarin I, Fastbom J, Wimo A. A population-based study of drug use in the very old living in a rural district of Sweden, with focus on cardiovascular drug consumption: comparison with an urban cohort. *Pharmacoepidemiol Drug Saf*. 2003;12(8):669–678.

29. Ayرانci U, Özdağ N. Health of elderly: importance of nursing and family medicine care. *Internet J Geriatr Gerontol*. 2005;3(1):1–4.

30. Sakuma M, Morimoto T, Matsu K, et al. Epidemiology of potentially inappropriate medication use in elderly patients in Japanese acute care hospitals. *Pharmacoepidemiol Drug Saf*. 2011;20(4):386–392.

31. Finlayson E, Maselli J, Steinman MA, Rothberg MB, Lindemauer PK, Auerbach AD. Inappropriate medication use in older adults undergoing surgery: a national study. *J Am Geriatr Soc*. 2011;59(11):2139–2144.

32. De Wilde S, Carey IM, Harris T, et al. Trends in potentially inappropriate prescribing amongst older UK primary care patients. *Pharmacoepidemiol Drug Saf*. 2007;16(6):658–667.

33. Vieira de Lima TJ, Garbin CA, Garbin AJ, Sumida DH, Saliba O. Potentially inappropriate medications used by the elderly: prevalence and risk factors in Brazilian care homes. *BMC Geriatr*. 2013;13:52.

34. Jhaveri BN, Patel TK, Barvaliya MJ, Tripathi C. Utilization of potentially inappropriate medications in elderly patients in a tertiary care teaching hospital in India. *Perspect Clin Res*. 2014;5(4):184–189.

35. Napolitano F, Izzo MT, Di Giuseppe G, Angelillo IF, Collaborative Working Group. Frequency of inappropriate medication prescription in hospitalized elderly patients in Italy. *PLoS One*. 2013;8(12):e82359.

36. Suzuki H, Shigeta A, Fukunaga T. Accidental death of elderly persons under the influence of chlorpheniramine. *Leg Med (Tokyo)*. 2013;15(5):253–255.

37. Golightly LK, Greos LS. Second-generation antihistamines: actions and efficacy in the management of allergic disorders. *Drugs*. 2005;65(3):341–384.

38. Marcum ZA, Hanlon JT. Recognizing the risks of chronic nonsteroidal anti-inflammatory drug use in older adults. *Ann Longterm Care*. 2010;18(9):24–27.

39. Castioni J, Marques-Vidal P, Abolhassani N, Vollenweider P, Waeger G. Prevalence and determinants of polypharmacy in Switzerland: data from the CoLaus study. *BMJ Health Serv Res*. 2017;17(1):840.

40. Harugeri A, Joseph J, Parthasarathi G, Ramesh M, Guido S. Potentially inappropriate medication use in elderly patients: a study of prevalence and predictors in two teaching hospitals. *J Postgrad Med*. 2010;56(3):186–191.

41. Banerjee A, Mbamalu D, Ebrahim S, Khan AA, Chan TF. The prevalence of polypharmacy in elderly attenders to an emergency department—a problem with a need for an effective solution. *Int J Emerg Med*. 2011;4(1):22.

42. Lau DT, Berka ND, Harris AT, Triffitshugh E, Shega J, Weintraub S. Polypharmacy and potentially inappropriate medication use among community-dwelling elders with dementia. *Alzheimer Dis Assoc Disord*. 2010;24(1):56–63.

43. Alhmoud E, Khalifa S, Bahi AA. Prevalence and predictors of potentially inappropriate medications among home care elderly patients in Qatar. *Int J Clin Pharm*. 2015;37(5):815–821.

44. Bao Y, Shao B, Bishop T, Schackman BR, Bruce ML. Inappropriate medication in a national sample of US elderly patients receiving home health care. *J Gen Intern Med*. 2012;27(3):304–310.

45. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. *Br J Clin Pharmacol*. 2010;69(5):543–552.

46. Fialova D, Topinkova E, Gambassi G, et al. Potentially inappropriate medication use among elderly home care patients in Europe. *JAMA*. 2005;293(11):1348–1358.

47. Chumney EC, Robinson LC. The effects of pharmacist interventions on patients with polypharmacy. *Pharm Pract*. 2006;4(3):103–109.

48. Hashimoto Y, Tensho M. Effect of pharmacist intervention on physician prescribing in patients with chronic schizophrenia: a descriptive pre/post study. *BMJ HealthServRes*. 2016;16:150.

49. Lin HY, Liao CC, Cheng SH, Wang PC, Hsueh YS. Association of potentially inappropriate medication use with adverse outcomes in ambulatory elderly patients with chronic diseases: experience in a Taiwanese medical setting. *Drugs Aging*. 2008;25(1):49–59.

50. Goulding MR. Inappropriate medication prescribing for elderly ambulatory care patients. *Arch Intern Med*. 2004;164(3):305–312.

51. Galli TB, Reis WC, Andrzejevski VM. Potentially inappropriate prescribing and the risk of adverse drug reactions in critically ill older adults. *Pharm Pract*. 2016;14(4):818.

52. Lund BC, Steinman MA, Chrischilles EA, Kaboli PJ. Beers criteria as a proxy for inappropriate prescribing of other medications among older adults. *Ann Pharmacother*. 2011;45(11):1363–1370.